Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Use of a Machine Learning Model to Predict Disability Progression in Patients with Relapsing Multiple Sclerosis Treated with Ozanimod (P6-6.006)
Jason Osik, Chun-Yen Cheng, Sarah Harris, Erik DeBoer, Léorah Freeman, Cristina Granziera, Massimo Filippi, Ludwig Kappos, Douglas L. Arnold, Chahin Pachaï, Nathanial R. Eddy (2024). Use of a Machine Learning Model to Predict Disability Progression in Patients with Relapsing Multiple Sclerosis Treated with Ozanimod (P6-6.006). , 102(17_supplement_1), DOI: https://doi.org/10.1212/wnl.0000000000204932.
Article48 days agoPresent and future of the diagnostic work-up of multiple sclerosis: the imaging perspective
Massimo Filippi, Paolo Preziosa, Douglas L. Arnold, Frederik Barkhof, Daniel M. Harrison, Pietro Maggi, Caterina Mainero, Xavier Montalbán, Elia Sechi, Brian G. Weinshenker, Maria A. Rocca (2022). Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective. , 270(3), DOI: https://doi.org/10.1007/s00415-022-11488-y.
Article48 days ago086 The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): results from reveal, a randomised, head-to-head study
Helmut Butzkueven, Douglas Jeffery, Douglas L. Arnold, Massimo Filippi, Jeroen J.G. Geurts, Qunming Dong, Nolan Campbell, Stephanie Licata, Pei‐Ran Ho (2018). 086 The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): results from reveal, a randomised, head-to-head study. , 89(6), DOI: https://doi.org/10.1136/jnnp-2018-anzan.85.
Article48 days agoWhite matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders
Giulia Longoni, Robert A. Brown, Parya MomayyezSiahkal, Colm Elliott, Sridar Narayanan, Amit Bar‐Or, Ruth Ann Marrie, E. Ann Yeh, Massimo Filippi, Brenda Banwell, Douglas L. Arnold (2017). White matter changes in paediatric multiple sclerosis and monophasic demyelinating disorders. , 140(5), DOI: https://doi.org/10.1093/brain/awx041.
Article48 days agoNatalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): comparative MRI assessments of disease activity from reveal, a randomized, head-to-head phase 4 study
Stephanie Licata, Helmut Butzkueven, Douglas Jeffery, Douglas L. Arnold, Massimo Filippi, Jeroen J.G. Geurts, Q. Dong, Nolan Campbell, Pei‐Ran Ho (2017). Natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): comparative MRI assessments of disease activity from reveal, a randomized, head-to-head phase 4 study. , 381, DOI: https://doi.org/10.1016/j.jns.2017.08.703.
Article48 days ago